ASH 2022

Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy 5:36
Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy
Veit Buecklein • 9 Dec 2022
CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL 1:23
CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL
Constantine Tam • 12 Dec 2022
The safety and efficacy of UCART123v1.2 in R/R AML: results from AMELI-01 2:52
The safety and efficacy of UCART123v1.2 in R/R AML: results from AMELI-01
David Sallman • 11 Dec 2022
Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML 2:08
Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML
David Sallman • 11 Dec 2022
Results from the first-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL 3:58
Results from the first-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL
Jakub Svoboda • 11 Dec 2022
Phase I study of CC-98633 in R/R multiple myeloma 2:45
Phase I study of CC-98633 in R/R multiple myeloma
Luciano Costa • 11 Dec 2022
Trials evaluating the efficacy of CD20 CAR-T cell therapy in WM and CNS lymphoma 1:00
Trials evaluating the efficacy of CD20 CAR-T cell therapy in WM and CNS lymphoma
Mazyar Shadman • 9 Dec 2022
The content of VJRegenMed is intended for healthcare professionals